86 related articles for article (PubMed ID: 37144508)
1. A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma.
Hwang GH; Pazyra-Murphy MF; Seo HS; Dhe-Paganon S; Stopka SA; DiPiazza M; Sutter N; Gero TW; Volkert A; Ombelets L; Dittemore G; Rees MG; Ronan MM; Roth JA; Agar NYR; Scott DA; Segal RA
Cancer Res; 2024 Mar; 84(6):872-886. PubMed ID: 38486486
[TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of MAGMAS inhibitor as a potential therapy for pediatric medulloblastoma.
Motahari Z; Lepe JJ; Bautista MR; Hoerig C; Plant-Fox AS; Das B; Fowler CD; Magge SN; Bota DA
bioRxiv; 2024 Mar; ():. PubMed ID: 38464047
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma.
Khang M; Lee JH; Lee T; Suh HW; Lee S; Cavaliere A; Rushing A; Geraldo LH; Belitzky E; Rossano S; de Feyter HM; Shin K; Huttner A; Roussel MF; Thomas JL; Carson RE; Marquez-Nostra B; Bindra RS; Saltzman WM
Sci Transl Med; 2023 Nov; 15(720):eadi1617. PubMed ID: 37910601
[TBL] [Abstract][Full Text] [Related]
4. The Proteasome Inhibitor CEP-18770 Induces Cell Death in Medulloblastoma.
Nath Varma S; Ye S; Ferlin S; Comer C; Cotton K; Niklison-Chirou MV
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794334
[TBL] [Abstract][Full Text] [Related]
5. Restore the brake on tumor progression.
Gordon RE; Zhang L; Yang ZJ
Biochem Pharmacol; 2017 Aug; 138():1-6. PubMed ID: 28389227
[TBL] [Abstract][Full Text] [Related]
6. Combination of PARP and WEE1 inhibitors
Lukoseviciute M; Theodosopoulou A; Holzhauser S; Dalianis T; Kostopoulou ON
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37144508
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines.
Lukoseviciute M; Holzhauser S; Pappa E; Mandal T; Dalianis T; Kostopoulou ON
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37477144
[TBL] [Abstract][Full Text] [Related]
8. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
9. A preliminary study on the mechanism of VASH2 in childhood medulloblastoma.
Liu W; Fu Y; Wang M; Zhao J; Chen J; Wang Y; Qin H
Sci Rep; 2023 Oct; 13(1):17153. PubMed ID: 37821528
[TBL] [Abstract][Full Text] [Related]
10. SHH inhibitors for the treatment of medulloblastoma.
Samkari A; White J; Packer R
Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
[TBL] [Abstract][Full Text] [Related]
11. Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.
Patil S; Sankpal UT; Hurtado M; Bowman WP; Murray J; Borgmann K; Ghorpade A; Sutphin R; Eslin D; Basha R
Gene; 2019 Jul; 705():67-76. PubMed ID: 30991098
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited.
Byskata K; Lukoseviciute M; Tuti F; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612094
[TBL] [Abstract][Full Text] [Related]
13. Medulloblastoma: WHO 2021 and Beyond.
Cotter JA; Hawkins C
Pediatr Dev Pathol; 2022; 25(1):23-33. PubMed ID: 35168417
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
